329 related articles for article (PubMed ID: 34680275)
1. Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance.
Rozengurt E; Eibl G
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680275
[TBL] [Abstract][Full Text] [Related]
2. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
3. Opposite Effects of Src Family Kinases on YAP and ERK Activation in Pancreatic Cancer Cells: Implications for Targeted Therapy.
Sinnett-Smith J; Anwar T; Reed EF; Teper Y; Eibl G; Rozengurt E
Mol Cancer Ther; 2022 Nov; 21(11):1652-1662. PubMed ID: 35999654
[TBL] [Abstract][Full Text] [Related]
4. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
5. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
[TBL] [Abstract][Full Text] [Related]
6. The Hippo Signaling Pathway in Pancreatic Cancer.
Ansari D; Ohlsson H; Althini C; Bauden M; Zhou Q; Hu D; Andersson R
Anticancer Res; 2019 Jul; 39(7):3317-3321. PubMed ID: 31262852
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK; Oni TE; Thalappillil JS; Park Y; Ting HC; Alagesan B; Prasad NV; Addison K; Rivera KD; Pappin DJ; Van Aelst L; Tuveson DA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34021083
[TBL] [Abstract][Full Text] [Related]
8. Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma.
Wang Y; Wang D; Dai Y; Kong X; Zhu X; Fan Y; Wang Y; Wu H; Jin J; Yao W; Gao J; Wang K; Xu H
Front Oncol; 2021; 11():652283. PubMed ID: 34046348
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
10. YAP in pancreatic cancer: oncogenic role and therapeutic strategy.
Mao W; Mai J; Peng H; Wan J; Sun T
Theranostics; 2021; 11(4):1753-1762. PubMed ID: 33408779
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms Associated with ROR1-Mediated Drug Resistance: Crosstalk with Hippo-YAP/TAZ and BMI-1 Pathways.
Karvonen H; Barker H; Kaleva L; Niininen W; Ungureanu D
Cells; 2019 Aug; 8(8):. PubMed ID: 31382410
[TBL] [Abstract][Full Text] [Related]
12. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
13. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
14. Targeting cell surface GRP78 enhances pancreatic cancer radiosensitivity through YAP/TAZ protein signaling.
Gopal U; Mowery Y; Young K; Pizzo SV
J Biol Chem; 2019 Sep; 294(38):13939-13952. PubMed ID: 31358620
[TBL] [Abstract][Full Text] [Related]
15. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
Zhang S; Chung WC; Xu K
Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
17. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
[TBL] [Abstract][Full Text] [Related]
18. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
[TBL] [Abstract][Full Text] [Related]
19. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.
Yang K; Li Y; Lian G; Lin H; Shang C; Zeng L; Chen S; Li J; Huang C; Huang K; Chen Y
Int J Cancer; 2018 Jun; 142(11):2323-2334. PubMed ID: 29315556
[TBL] [Abstract][Full Text] [Related]
20. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
